Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells.
Aruljothi Mariappan,Komal Soni,Kenji Schorpp,Fan Zhao,Amin Minakar,Xiangdong Zheng,Sunit Mandad,Iris Macheleidt,Anand Ramani,Tomáš Kubelka,Maciej Dawidowski,Kristina Golfmann,Arpit Wason,Chunhua Yang,Judith Simons,Hans-Günther Schmalz,Anthony A Hyman,Ritu Aneja,Roland Ullrich,Henning Urlaub,Margarete Odenthal,Reinhardt Büttner,Haitao Li,Michael Sattler,Kamyar Hadian,Jay Gopalakrishnan
DOI: https://doi.org/10.15252/embj.201899876
2019-01-01
Abstract:Centrosome amplification is a hallmark of human cancers that can trigger cancer cell invasion. To survive, cancer cells cluster amplified extra centrosomes and achieve pseudobipolar division. Here, we set out to prevent clustering of extra centrosomes. Tubulin, by interacting with the centrosomal protein CPAP, negatively regulates CPAP-dependent peri-centriolar material recruitment, and concurrently microtubule nucleation. Screening for compounds that perturb CPAP-tubulin interaction led to the identification of CCB02, which selectively binds at the CPAP binding site of tubulin. Genetic and chemical perturbation of CPAP-tubulin interaction activates extra centrosomes to nucleate enhanced numbers of microtubules prior to mitosis. This causes cells to undergo centrosome de-clustering, prolonged multipolar mitosis, and cell death. 3D-organotypic invasion assays reveal that CCB02 has broad anti-invasive activity in various cancer models, including tyrosine kinase inhibitor (TKI)-resistant EGFR-mutant non-small-cell lung cancers. Thus, we have identified a vulnerability of cancer cells to activation of extra centrosomes, which may serve as a global approach to target various tumors, including drug-resistant cancers exhibiting high incidence of centrosome amplification.